Medpace Holdings earnings beat by $0.40, revenue topped estimates

Medpace Holdings (MEDP) reported Q3 EPS of $4.84, beating estimates by $0.40, with revenue of $716M, slightly above expectations. The company provided FY 2026 guidance, with EPS and revenue estimates close to consensus. The stock is up 20.90% over the past year and has seen 8 positive EPS revisions in the last 90 days, according to Investing.com.

Original reporting
Published Oct 21, 2026, 8:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 8:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$MEDP
Bullish
medium confidence
Mentioned
$MEDP
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$MEDPBullishMed
01

Why it matters

The key tradable inputs are the EPS and revenue beats plus the FY 2026 EPS and revenue ranges, which can shift forward estimates and valuation multiples.

02

Market read

A company-specific earnings and guidance update that can drive near-term repricing of forward earnings expectations.

03

What to watch

The article does not break out segment growth, client concentration, or margin drivers, which can dominate post-earnings follow-through even when EPS beats.

Relevance 8/10Novelty 7/10Timing: after-hours earnings release and guidance update

Background

Medpace Holdings is a clinical research services provider; this article summarizes its Q3 results and FY 2026 guidance versus analyst consensus.

Company-level read

Ticker impact

$MEDPBullishMedium confidence
Context

Medpace reported Q3 EPS of $4.84, beating the $4.44 estimate, and revenue of $716M versus $714.47M, plus FY 2026 EPS and revenue guidance.

Expected impact

Likely upward bias as the market prices in stronger-than-expected earnings power and modestly higher FY 2026 outlook.

Evidence & confidence

The article provides both the earnings beat and explicit FY 2026 EPS and revenue ranges versus consensus, which are direct inputs to valuation and expectations.

Market effects

Reinforces demand and pricing resilience signals for clinical research services, though the article is single-name and not a sector-wide datapoint.

Limited, as it is a US-listed single-company earnings print without broader macro linkage.

Low, no international regulatory or cross-border deal details beyond the company’s own results.

Counterpoint

The revenue beat is marginal versus consensus, so the stock reaction may hinge more on the quality of guidance and margins than on the headline EPS outperformance.

Key entities

  • Medpace Holdings

    Reported Q3 EPS and revenue versus consensus and issued FY 2026 EPS and revenue guidance ranges.

Related articles

$MEDPMedAI 8/10

MEDP Q3 deep dive: bookings strength drives growth, margin expansion continues

MEDP reported Q3 revenue of $716M, beating estimates, with EPS of $4.84 and adjusted EBITDA of $172.1M. The company reconfirmed full-year revenue guidance of $2.85B and raised EPS guidance to $18.15. Growth was driven by strong bookings in oncology research and margin expansion from a favorable project mix. Management highlighted stable competition, low turnover, and sustained bookings momentum, but noted project cancellations as a watchpoint.

$MEDPMedAI 8/10

Medpace 3Q 2026: Revenue $716M, EPS $4.84— 10-Q Summary

Medpace Holdings reported Q3 2026 revenue of $716M, up 8.5% YoY, with net income rising 23.7% to $137.46M and EPS increasing 25.4% to $4.84. Growth was driven by Metabolic, Oncology, and CNS services. Nine-month revenue grew 16.9%, net awards reached $873.4M, and backlog increased 5.6% YoY to $3.17B. The company plans organic growth and selective acquisitions.

$MEDPHighAI 8/10

Medpace (MEDP) Q3 2026 Earnings Call Transcript

Medpace (MEDP) reported Q3 2026 revenue of $716M, up 8.5% YoY, with EBITDA of $172.1M (up 16%) and net income of $137.5M (up 23.7%). Guidance raised: revenue $2.835B-$2.855B (12-12.8% growth), EBITDA $638M-$652M (14.4-16.9% growth), EPS $17.97-$18.32. Board approved $1B share repurchase program. Net new business awards up 10.6% QoQ.

$MEDPMed

Medpace Q3 Earnings Call Highlights

Medpace reported a 10.6% year-over-year increase in net new business awards to $873.4 million in Q3, with a total 12-month backlog of $3.02 billion. Ending backlog was $3.2 billion, up 5.6% year-over-year. The company expects $1.99 billion of backlog to convert into revenue over the next year. Management noted shifts in therapeutic mix and strong pending opportunities. Medpace plans to provide 2027 guidance in February, with fourth-quarter awards and cancellations influencing the outlook.

$MEDPHighAI 8/10

Medpace Q3 2026 slides: record awards fuel profit beat, guidance raised

Medpace Holdings (NASDAQ:MEDP) reported Q3 2026 revenue of $716.0M, up 8.5% YoY, and adjusted earnings of $4.84 per share, exceeding estimates. Net income rose 23.7% to $137.5M, with EBITDA margin widening to 24.0%. The company raised its full-year guidance, citing record new business awards and strong profitability trends. Shares traded near $659.37, close to their 52-week high.